Antifibrotic effects of pirfenidone in rat proximal tubular epithelial cells

Renal Failure

Volumn 34, Issue 10, 2012, Pages 1309-1316

  Takakura, Koji ^a   Tahara, Atsuo ^a   Sanagi, Masanao ^a   Itoh, Hiroyuki ^a   Tomura, Yuichi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Pirfenidone; Platelet derived growth factor; Renal fibrosis; Transforming growth factor 1

Indexed keywords

COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PIRFENIDONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; EXTRACELLULAR MATRIX; KIDNEY FIBROSIS; KIDNEY TUBULE EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION;

ANIMALS; CELLS, CULTURED; EPITHELIAL CELLS; FIBROSIS; KIDNEY TUBULES, PROXIMAL; PYRIDONES; RATS; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; UROTHELIUM;

EID: 84867700062     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2012.718955     Document Type: Article

References (44)

1. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis. 2005;12:353-"365. (Pubitemid 41376493)
2. Boor P, Ostendorf T, Floege J. Renal fibrosis: Novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol. 2010;6:643-"656.
3. Negri AL. Prevention of progressive fibrosis in chronic renal diseases: Antifibrotic agents. J Nephrol. 2004;17:496-"503. (Pubitemid 39302876)
4. Declèves AE, Sharma K. New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol. 2010;6:371-"380.
5. Wight TN, Potter-Perigo S. The extracellular matrix: An active or passive player in fibrosis? Am J Physiol. 2011;301: G950-"G955.
6. Sharma SK, Ziyadeh FN. The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol. 1994;266: F829-"F842.
7. Gagliardini E, Benigni A. Therapeutic potential of TGF-beta inhibition in chronic renal failure. Expert Opin Biol Ther. 2007;7:293-"304. (Pubitemid 46383473)
8. Ma LJ, Fogo AB. PAI-1 and kidney fibrosis. Front Biosci. 2009;14:2028-"2041.
9. Eddy AA. Serine proteases, inhibitors and receptors in renal fibrosis. Thromb Hemost. 2009;101:656-"664.
10. Fan JM, Ng YY, Hill PA, et al. Transforming growth factor-beta regulates tubular epithlial-myofibroblast transdifferentiation in vitro. Kidney Int. 1999;56:1455-"1467. (Pubitemid 29451252)
11. Burns WC, Kantharidis P, Thomas MC. The role of tubular epithelial-mesenchymal transition in progressive kidney disease. Cells Tissues Organs. 2007;185:222-"231. (Pubitemid 46956862)
12. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol. 2010;21:212-"222.
13. Fukasawa H, Yamamoto T, Suzuki H, et al. Treatment with anti-TGF-β antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-β signaling. Kidney Int. 2004;65:63-"74. (Pubitemid 38037492)
14. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821-"829.
15. Maher TM. Pirfenidone in idiopathic pulmonary fibrosis. Drugs Today. 2010;46:473-"482.
16. Macias-Barragan J, Sandoval-Rodriguez A, Navarro-Partida J, Armendariz-Borunda J. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tiss Rep. 2010;3:16.
17. Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB, Kurokawa K. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int. 1998;54:99-"109. (Pubitemid 28288024)
18. Shimizu T, Fukagawa M, Kuroda T, et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl. 1997;63:S239-"S243.
19. Takakura K, Fujimori A, Chikanishi T, et al. Renoprotective properties of pirfenidone in subtotally nephrectomized rats. Eur J Pharmacol. 2010;629:118-"124.
20. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of pirfenidone ameliorates bleomycininduced lung fibrosis in hamsters. J Lab Clin Med. 1995; 125:779-"785.
21. Nakayama S, Mukae H, Sakamoto N, et al. Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci. 2008;82:210-"217.
22. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011;20:85-"97.
23. Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol. 2008;19:12-"23.
24. Ostendorf T, Kunter U, Grone HJ, et al. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol. 2001;12:909-"918. (Pubitemid 32378331)
25. Ostendorf T, Eitner F, The FJ. PDGF family in renal fibrosis. Pediatr Nephrol. 2011;26(9):2728-"2731 (online).
26. Yamate J. Heterogeneity of macrophage populations and myofibroblasts appearing in rat renal interstitial fibrosis. J Toxicol Pharmacol. 2007;20:185-"195.
27. Shimizu F, Fukagawa M, Yamauchi S, et al. Pirfenidone prevents the progression of irreversible glomerular sclerotic lesions in rats. Nephrology. 1997;3:315-"322. (Pubitemid 27438654)
28. Hammes MS, Lieske JC, Pawar S, Spargo BH, Toback FG. Calcium oxalate monohydrate crystals stimulate gene expression in renal epithelial cells. Kidney Int. 1995;48:501-"509.
29. Zhang G, Kim H, Cai X, Lopez-Guisa JM, Carmeliet P, Eddy AA. Urokinase receptor modulates cellular and angiogenic responses in obstructive nephropathy. J Am Soc Nephrol. 2003; 14:1234-"1253. (Pubitemid 36514665)
30. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol. 2000;15:290-"301.
31. MaJ, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int. 2006; 69:1064-"1072. (Pubitemid 43372182)
32. Shihab FS, Bennett WM, Yi H, Andoh TF. Pirfenidone treatment decreases transforming growth factor-β1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant. 2002;2:111-"119. (Pubitemid 36306789)
33. Ikushima H, Komuro A, Isogaya K, et al. An Id-like molecule, HHM, is a synexpression group-restricted regulator of TGF-β signaling. EMBO J. 2008;27:2955-"2965.
34. Schiller M, Dennler S, Anderegg U, et al. Increased cAMP levels modulate transforming growth factor-beta/Smad-induced expression of extracellular matrix components and other key fibroblast effector functions. J Biol Chem. 2010;285:409-"421.
35. Samarakoon R, Higgins PJ. Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. Thromb Hemost. 2008;100:976-"983.
36. Zhang Y, Feng XH, Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature. 1998;27:909-"913. (Pubitemid 28410915)
37. Ozes ON, Stevens SK, Phillips RJ, Blatt LM. Pirfenidone attenuates transforming growth factor-beta-induced activation of P38-Alpha and P38-gamma mitogen-Activated protein kinases in human lung fibroblasts: Implications for treatment of fibrotic lung diseases. Chest. 2006;130:114S (Abstract).
38. Cirit M, Wang CC, Haugh JM. Systematic quantification of negative feedback mechanisms in the extracellular signalregulated kinase (ERK) signaling network. J Biol Chem. 2010;285:36736-"36744.
39. Frazier KS, Paredes A, Dube P, Styer E. Connective tissue growth factor expression in the rat remnant kidney model and association with tubular epithelial cells undergoing transdifferentiation. Vet Pathol. 2000;37:328-"335.
40. Sommer M, Eismann U, Deuther-Conrad W, et al. Time course of cytokine mRNA expression in kidneys of rats with unilateral ureteral obstruction. Nephron. 2000;84:49-"57. (Pubitemid 30066142)
41. Creely JJ, Dimari SJ, Howe AM, Haralson MA. Effects of transforming growth factor-beta on collagen synthesis by normal rat kidney epithelial cells. Am J Pathol. 1992;140:45-"55.
42. Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med. 2008;233:109-"122. (Pubitemid 351231543)
43. Yuan Q, Wang L, Zhang F, et al. Fluorofenidone suppresses epithelial-mesenchymal transition and the expression of connective tissue growth factor via inhibiting TGF-β/Smads signaling in human proximal tubular epithelial cells. Pharmazie. 2011;66:961-"967.
44. Grgic I, Duffield JS, Humphreys BD. The origin of interstitial myofibroblasts in chronic kidney disease. Pediatr Nephrol. 2012;27:183- "193.